摘要
目的:探讨曲美他嗪与依折麦布联合治疗冠心病患者的效果及对低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、甘油三酯(TG)水平的影响。方法:选取2018年1月-2020年12月大连市中心医院收治的冠心病患者90例,根据治疗方法分为两组,对照组采用曲美他嗪治疗,研究组采用曲美他嗪与依折麦布联合治疗。比较两组治疗效果、血脂水平、氧化应激反应、平板运动试验结果、炎症因子情况。结果:研究组治疗总有效率高于对照组(P<0.05);治疗后,研究组高密度脂蛋白胆固醇(HDL-C)高于对照组(P<0.05),LDL-C、TG、TC均低于对照组(P<0.05);治疗后,研究组过氧化物酶(MPO)、丙二醇(MDA)均低于对照组(P<0.05),超氧化物歧化酶(SOD)高于对照组(P<0.05);治疗后,研究组ST段下移1 mm时间、诱发心绞痛发作时间、运动持续时间均较对照组长(P<0.05);治疗后,研究组肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)均低于对照组(P<0.05)。结论:在冠心病患者治疗中,曲美他嗪与依折麦布联合治疗效果显著,值得应用。
Objective:To investigate the effect of Trimetazidine combined with Ezetimibe in the treatment of patients with coronary heart disease and its influence on the levels of LDL-C,TC and TG.Method:A total of 90 patients with coronary heart disease in Dalian Central Hospital from January 2018 to December 2020 were selected and divided into two groups according to the treatment method.The control group was treated with Trimetazidine,and the study group was treated with Trimetazidine and Ezetimibe.The treatment results,blood lipid level,oxidative stress reaction,treadmill exercise test results and inflammatory factors were compared between the two groups.Result:The total effective rate of the study group was higher than that of the control group(P<0.05);after treatment,high density lipoprotein cholesterol(HDL-C)in the study group was higher than that in the control group(P<0.05),and LDL-C,TG and TC were lower than those in the control group(P<0.05);after treatment,MPO and MDA in the study group were lower than those in the control group(P<0.05),and superoxide dismutase(SOD)was higher than that in the control group(P<0.05);after treatment,the time of ST segment moving down by 1 mm,the time of inducing angina pectoris and the duration of exercise in the study group were longer than those in the control group(P<0.05);after treatment,tumor necrosis factor-α(TNF-α),hypersensitive C-reactive protein(hs-CRP)were lower than those in the control group(P<0.05).Conclusion:In the treatment of patients with coronary heart disease,Trimetazidine combined with Ezetimibe has significant effect,which is worthy of application.
作者
张莹
ZHANG Ying(Dalian Central Hospital,Liaoning Province,Dalian 116011,China)
出处
《中国医学创新》
CAS
2022年第2期61-65,共5页
Medical Innovation of China
关键词
曲美他嗪
依折麦布
冠心病
低密度脂蛋白胆固醇
甘油三酯
总胆固醇
Trimetazidine
Ezetimibe
Coronary heart disease
Low density lipoprotein cholesterol
Triglyceride
Total cholesterol
